<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="57818"><DrugName>PF-4136309</DrugName><DrugSynonyms><Name><Value>PF-4136309</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PF-04136309</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>INCB-8761</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17216">Incyte Corp</CompanyOriginator><CompaniesSecondary><Company id="17216">Incyte Corp</Company><Company id="18767">Pfizer Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="57818" type="Drug"><TargetEntity id="459297" type="siDrug">INCB-8761</TargetEntity></SourceEntity><SourceEntity id="17216" type="Company"><TargetEntity id="4295906783" type="organizationId">Incyte Corp</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="1507" type="ciIndication"><TargetEntity id="D021441" type="MeSH"></TargetEntity><TargetEntity id="1858" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="154" type="ciIndication"><TargetEntity id="10019717" type="MEDDRA"></TargetEntity><TargetEntity id="D006505" type="MeSH"></TargetEntity><TargetEntity id="-1968993298" type="omicsDisease"></TargetEntity><TargetEntity id="424" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2318" type="ciIndication"><TargetEntity id="K74.0" type="ICD10"></TargetEntity><TargetEntity id="10019668" type="MEDDRA"></TargetEntity><TargetEntity id="423" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3098" type="Action"><TargetEntity id="1610" type="Mechanism">Anti-CCR2</TargetEntity><TargetEntity id="991" type="Mechanism">Chemokine CCR2 (MCP-1 Receptor) Antagonists</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication><Indication id="154">Hepatitis</Indication><Indication id="20">Pain</Indication><Indication id="2318">Liver fibrosis</Indication><Indication id="249">Pancreas tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3098">CCR2 chemokine antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="2946">Analgesic</Action><Action id="664">Fibrosuppressant</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-06-04T16:58:44.000Z</LastModificationDate><ChangeDateLast>2018-05-24T00:00:00.000Z</ChangeDateLast><AddedDate>2007-08-07T15:49:54.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt;,  under license from &lt;ulink linkID="17216" linkType="Company"&gt;Incyte&lt;/ulink&gt;,    was developing   PF-4136309 (PF-04136309, INCB-8761), an oral  CCR2 antagonist, for the potential treatment of pancreatic cancer [&lt;ulink linkID="819965" linkType="Reference"&gt;819965&lt;/ulink&gt;], [&lt;ulink linkID="1731485" linkType="Reference"&gt;1731485&lt;/ulink&gt;]. In May 2016,  a phase Ib/II trial for pancreatic ductal adenocarcinoma was initiated in  the US [&lt;ulink linkID="1755761" linkType="Reference"&gt;1755761&lt;/ulink&gt;]; in September 2017, data were presented [&lt;ulink linkID="1960308" linkType="Reference"&gt;1960308&lt;/ulink&gt;], [&lt;ulink linkID="1960305" linkType="Reference"&gt;1960305&lt;/ulink&gt;]. In December 2015, a phase I study was initiated    [&lt;ulink linkID="1716498" linkType="Reference"&gt;1716498&lt;/ulink&gt;]. In February 2016, Pfizer listed the drug as having entered phase I trials for pancreatic cancer  since October 2015  [&lt;ulink linkID="1731485" linkType="Reference"&gt;1731485&lt;/ulink&gt;]; this was still the case in October 2017 [&lt;ulink linkID="1978769" linkType="Reference"&gt;1978769&lt;/ulink&gt;]. However, in May 2018, Pfizer listed the drug as discontinued on its pipeline [&lt;ulink linkID="2036946" linkType="Reference"&gt;2036946&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously in development for other indications; initially for osteoarthritic pain, followed by liver fibrosis and   hepatitis, including that associated with hepatitis C virus  (HCV) infection    [&lt;ulink linkID="636024" linkType="Reference"&gt;636024&lt;/ulink&gt;], [&lt;ulink linkID="883033" linkType="Reference"&gt;883033&lt;/ulink&gt;],      [&lt;ulink linkID="1149070" linkType="Reference"&gt;1149070&lt;/ulink&gt;].  A phase II trial in osteoarthritic pain began in August 2008 [&lt;ulink linkID="915082" linkType="Reference"&gt;915082&lt;/ulink&gt;].  However, by January 2010,  pain trials had been discontinued   [&lt;ulink linkID="1071193" linkType="Reference"&gt;1071193&lt;/ulink&gt;]. In January  2011, Pfizer began a phase II trial in patients with chronic HCV infection [&lt;ulink linkID="1149070" linkType="Reference"&gt;1149070&lt;/ulink&gt;]. From May  2011 to November 2011, the compound was listed as in phase II for liver fibrosis on Pfizer's pipeline  [&lt;ulink linkID="1191886" linkType="Reference"&gt;1191886&lt;/ulink&gt;], [&lt;ulink linkID="1241448" linkType="Reference"&gt;1241448&lt;/ulink&gt;]. However, in February 2012, the drug was listed as having been discontinued by Pfizer for this indication [&lt;ulink linkID="1267798" linkType="Reference"&gt;1267798&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In July 2017, the US FDA granted Orphan designation to an antagonist of chemokine ligand-2 (CCL2), presumed to be  PF-4136309, for treatment of pancreatic cancer [&lt;ulink linkID="1944635" linkType="Reference"&gt;1944635&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Pancreatic cancer&lt;/subtitle&gt;In February 2016, an open-label,  phase Ib/II study (&lt;ulink linkID="258462" linkType="Protocol"&gt;NCT02732938&lt;/ulink&gt;; A9421018) of the drug in combination with nab-paclitaxel and gemcitabine, to evaluate the safety, efficacy and toxicity  in patients (expected n = 112) with previously untreated metastatic pancreatic ductal adenocarcinoma was to begin in the US in March 2016. The trial was to complete in August 2018. In May 2016, the trial was initiated in  the US [&lt;ulink linkID="1755761" linkType="Reference"&gt;1755761&lt;/ulink&gt;]. In September 2017, data from the trial were presented at the ESMO 2017 Congress in Madrid, Spain, Patients received PF-04136309 (500 or 750 mg po, bid; n = 17 and 4, respectively), plus nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) on days 1, 8 and 15 of a 28-day cycle.  A third of patients treated with the combination showed a best overall response of partial response (n = 6 and 1 in 500- and 750-mg cohorts, respectively) with decreases in tumor size from baseline of 30 to 90%. Dosing with PF-04136309 also resulted in complete inhibition of CCL2-induced ERK phosphorylation in CD14+ monocytes, a decrease in CD14+CCL2+ monocytes and an increase in tumor-associated T cells in these patients. Rapid absorption of the drug was observed, with a Tmax of 1 and 1.4 h for the 750- and 500-mg cohorts, respectively. The respective Cmax, AUC and clearance values were 2950 and 1408 ng/ml, 10,600 and 5872 ng.h/ml, and 51.5 and 93.9 l/h. The combination was found to be tolerable with a safety profile consistent with that observed for a monotherapy treatment and with FOLFIRINOX [&lt;ulink linkID="1960308" linkType="Reference"&gt;1960308&lt;/ulink&gt;], [&lt;ulink linkID="1960305" linkType="Reference"&gt;1960305&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Liver fibrosis&lt;/subtitle&gt;In October 2010, Pfizer planned a  randomized, double-blind, placebo  controlled, phase II    trial (&lt;ulink linkID="71555" linkType="Protocol"&gt;NCT01226797&lt;/ulink&gt;, A9421016),  of PF-4136309 (500 mg , bid, po), in patients (expected n =  62), with chronic  HCV infection and abnormal liver enzymes. At that time, the study was expected to  begin in December 2010. The trial began in January 2011, with an estimated study completion date   in  October  of that year.   In December 2011, the trial was terminated  due to difficulty in enrolling the targeted number of patients. There were no safety concerns   associated with the trial [&lt;ulink linkID="1149070" linkType="Reference"&gt;1149070&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Osteoarthritic pain&lt;/subtitle&gt;In August 2008, a US and Korean, randomized, double-blind, placebo-controlled phase II trial (&lt;ulink linkID="18515" linkType="Protocol"&gt;NCT00689273&lt;/ulink&gt;; A9421006) began in subjects (expected n = 152) with osteoarthritic pain of the knee. Patients would receive PF-4136309 as four 125 mg capsules bid for 2 weeks, and the primary outcome measure would be the change from baseline (Day 1) to week 2 (Day 14) in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain domain score. The trial was estimated to complete in May 2009. In   November 2008, the trial was completed with 157 participants [&lt;ulink linkID="915082" linkType="Reference"&gt;915082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;In November 2015, an open-label, randomized, single dose, two-period, crossover, pharmacokinetic, phase I study (&lt;ulink linkID="245133" linkType="Protocol"&gt;NCT02598206&lt;/ulink&gt;; A9421019; 2015-003649-24) was planned to be initiated in  Belgium, in healthy volunteers (expected n = 18) to evaluate the effect of food intake on PF-04136309 pharmacokinetics following a single dose at 1000 mg. At that time, the study was expected to complete in February 2016. In December 2015, the trial was initiated; in  May 2016, the trial was completed [&lt;ulink linkID="1716498" linkType="Reference"&gt;1716498&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By July 2007, phase I pain trials had begun [&lt;ulink linkID="819965" linkType="Reference"&gt;819965&lt;/ulink&gt;],  [&lt;ulink linkID="883033" linkType="Reference"&gt;883033&lt;/ulink&gt;]; and  phase I  trials for liver disease were initiated by February 2008 [&lt;ulink linkID="883033" linkType="Reference"&gt;883033&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2017, in vivo data were presented at the 108th AACR Annual Meeting in Washington DC. In ID8-Luc2 tumor-bearing mice, among ascites myeloid cells, PF-04136309 reduced the frequency of CCR2+ myeloid cells; while among CD45+ leukocytes, PF-04136309 did not affect the frequency of ascites total myeloid cells. In doxorubicin treated mice bearing ovarian carcinoma ID8-Luc2 tumors, PF-04136309 exhibited a strong synergy with doxorubicin. In mice orthotopically implanted with Pan02-Luc2 pancreatic carcinoma cells, day 28 and 35 the addition of PF-04136309 to gemcitabine/paclitaxel exhibited decreased tumor burden, which was beyond the reduction observed with chemotherapy treatment alone [&lt;ulink linkID="1914266" linkType="Reference"&gt;1914266&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, preclinical data were presented at the 2016 ATS International Conference in San Francisco, CA. In CCR5Ki mice, &lt;ulink linkID="66081" linkType="Drug"&gt;PF-4634817&lt;/ulink&gt; (7.5 mg/kg/day) prevented the hypoxia induced pH to a greater extent compared with PF-4136309 (100 mg/kg/day) and &lt;ulink linkID="37613" linkType="Drug"&gt;maraviroc&lt;/ulink&gt; (200 mg/kg/day) [&lt;ulink linkID="1767891" linkType="Reference"&gt;1767891&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2005, Pfizer licensed  exclusive worldwide development and commercialization rights to the CCR2 antagonists. Pfizer's rights extended to all potential indications, excluding multiple sclerosis and one other undisclosed indication, where Incyte retained rights [&lt;ulink linkID="636024" linkType="Reference"&gt;636024&lt;/ulink&gt;]; later disclosed to be    lupus nephritis [&lt;ulink linkID="838023" linkType="Reference"&gt;838023&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="154">Hepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-02-28T00:00:00.000Z</StatusDate><Source id="1267798" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-05-01T00:00:00.000Z</StatusDate><Source id="2036946" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-05-01T00:00:00.000Z</StatusDate><Source id="2036946" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="154">Hepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-02-28T00:00:00.000Z</StatusDate><Source id="1267798" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-08-21T00:00:00.000Z</StatusDate><Source id="915082" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-01-27T00:00:00.000Z</StatusDate><Source id="1071193" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2318">Liver fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-02-28T00:00:00.000Z</StatusDate><Source id="1267798" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="154">Hepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-02-28T00:00:00.000Z</StatusDate><Source id="1267798" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-01-27T00:00:00.000Z</StatusDate><Source id="1071193" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2318">Liver fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-11-04T00:00:00.000Z</StatusDate><Source id="1716498" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="154">Hepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-11-04T00:00:00.000Z</StatusDate><Source id="1716498" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2318">Liver fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-09T00:00:00.000Z</StatusDate><Source id="1716498" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="154">Hepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-09T00:00:00.000Z</StatusDate><Source id="1716498" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="154">Hepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-01-31T00:00:00.000Z</StatusDate><Source id="1149070" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="154">Hepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-01-31T00:00:00.000Z</StatusDate><Source id="1149070" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2318">Liver fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-05-12T00:00:00.000Z</StatusDate><Source id="1191886" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="154">Hepatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-01-31T00:00:00.000Z</StatusDate><Source id="1149070" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17216">Incyte Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-21T00:00:00.000Z</StatusDate><Source id="636024" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-31T00:00:00.000Z</StatusDate><Source id="1716498" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-05-06T00:00:00.000Z</StatusDate><Source id="1755761" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-07-31T00:00:00.000Z</StatusDate><Source id="819965" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-21T00:00:00.000Z</StatusDate><Source id="636024" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-08-21T00:00:00.000Z</StatusDate><Source id="915082" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-08-21T00:00:00.000Z</StatusDate><Source id="915082" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2318">Liver fibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-02-28T00:00:00.000Z</StatusDate><Source id="883033" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18767">Pfizer Inc</OwnerCompany><Country id="US">US</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-07-03T00:00:00.000Z</MileStoneDate><Source id="1944635" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00351"><Name>CCR2 chemokine</Name><SwissprotNumbers><Swissprot>O18793</Swissprot><Swissprot>O55193</Swissprot><Swissprot>P41597</Swissprot><Swissprot>P51683</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2036946" linkType="reference" linkID="2036946"&gt;2036946&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17216">Incyte Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cc(cc(c1)C(=O)NCC(=O)N2C[C@H](CC2)N[C@H]3CC[C@@](CC3)(O)c4ncc(cc4)c5ncccn5)C(F)(F)F</Smiles></StructureSmiles><Deals><Deal id="108413" title="Pfizer to develop Incyte's CCR2/CCR5 antagonists worldwide "></Deal></Deals><PatentFamilies><PatentFamily id="2150333" number="WO-2012114223" title="A method of treating liver fibrosis"></PatentFamily><PatentFamily id="349119" number="WO-2005060665" title="3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Incyte Corp" id="17216"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>